2. Academic Validation
  3. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens

Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens

  • Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02255-19. doi: 10.1128/AAC.02255-19.
M Biagi 1,  A Shajee 1,  A Vialichka 2,  M Jurkovic 2,  X Tan 2,  E Wenzler 3
Affiliations

Affiliations

  • 1 College of Pharmacy, University of Illinois at Chicago, Rockford, Illinois, USA.
  • 2 College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.
  • 3 College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA [email protected].
PMID: 31932381 DOI: 10.1128/AAC.02255-19
Abstract

The Serratia marcescens Enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.

Keywords

SME; Serratia marcescens; carbapenem-resistant Enterobacteriaceae; imipenem-relebactam; meropenem-vaborbactam.

Figures
Products